Fabrication and Characterization of Nanoparticles Based Matrix Tablets of Flurbiprofen for Sustained Drug Delivery System.

Main Article Content

Shrikrushna A. Shinde
Parulben D. Mehta

Abstract

The objective of existing work was development by keeping two objectives in mind, firstly to prepare and evaluate flurbiprofen (FBL) loaded nanoparticles and secondly, fabrication of nanoparticles loaded matrix tablets through wet-granulation.Using particle-size, zeta-potential, and entrapment effectiveness as determinants, physiochemical characteristics of FBL-loaded nanoparticles were determined. Spectroscopy techniques like X-ray powder diffraction and differential scanning calorimetry as well as infrared spectroscopy were used to investigate the nanoparticles (PXRD). All batches of nanoparticles were subjected to in vitro dissolving investigations using modified USP dissolution equipment, and the data was evaluated using zero & first order, Higuchi, Korsmeyer, and Hixson-Crowell equations.The resulting FBL nanoparticles were physically stable and had particles that ranged in size from 150 to 350 nm. Overall drug-release of FBL through matrix tablets was found sustain up to 16 hrs. The drug release kinetics profiles revealed that all the formulations follow non-Fickianmechanism.

Article Details

How to Cite
Shrikrushna A. Shinde, & Parulben D. Mehta. (2022). Fabrication and Characterization of Nanoparticles Based Matrix Tablets of Flurbiprofen for Sustained Drug Delivery System. Journal of Coastal Life Medicine, 10(3), 438–457. Retrieved from https://www.jclmm.com/index.php/journal/article/view/217
Section
Articles

References

S. Suresh, B.K. Ahuja, S.K. Jena, S.K. Paidi, S. Bagri, Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension, Int.J.Pharm. 478 (2015)540–552.

S. Verma, R. Gokhale, D.J. Burgess, A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int.J. Pharma. 380 (2009)216–222.

A. Shrivastava, S. Sakthivel, B. Pitchumani, A.S. Rathore, A statistical approach for estimation of significant variables in wet attrition milling: Powder Technol. 211 (2011)46–53.

R.M. Khalil, M.A. Kassem, A.A. Abdel Rahman, M.M. Ghorab, M.B. Ahmed, Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340 (2007)126–133.

I. Ghosh, S. Bose, R. Vippagunta,F. Harmon, Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int. J. Pharm. 409 (2011)260–268.

Y. Wang, X. Hu, X. Chen, X. Lin, L. Zhang, X. Tang,et al. A combined bottom-up/top-down approach to prepare a sterile injectable nanosuspension. Int. J. Pharm. 472 (2014)130–139.

R.H. Muller, C.M. Keck, Twenty years of drug nanocrystals: where are we and where do we go? Eur. J. Pharm. Biopharm. 80 (2012) 1-3.

X. Zhang, J. Guan, R. Ni, L.C. Li, S. Mao,Preparation and Solidification of redispersiblenanosuspensions. J. Pharm. Sci. 103 (2014)2166–2176.

P.P. Ige, R.K. Baria, S.G. Gattani, Fabrication of fenofibratenanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability, Colloids Surf. B. Bio-interfaces 108 (2013) 366– 373.

F. Cui, D. Xia, P. Quan, H. Piao, S. Sun, Y. Yin, et al. lPreparation of stable nitrendipinenanosuspensions using the precipitation–utrasonication method for enhancement of dissolution and oral bioavailability. Eur. J. Pharm. Sci. 40 (2010) 325–334.

T. Niwa, S. Miura, K. Danjo,Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies development of particle design method. Int. J. Pharm. 405 (2011) 218–227.

Z. Bujanakova, E. Dutkova,M. Balaz,E. Turianicova,P. Balaz, Stability studies of As4S4nanosuspension prepared by wet milling in poloxamer 407. Int. J. Pharm. 478 (2011) 187–192.

X. Tang,H. Yang,F. Teng,P. Wang,B. Tian,X. Lin,et al. Investigation of nanosuspension stabilized by Soluplus to improve bioavailability. Int. J. Pharm. 477 (2014) 88-95.

C.M. Patel, M. Chakraborty, Z.V. Murthy,Preparation of fenofibrate nanoparticles by combined stirred media milling and ultrasonication method. Ultrason. Sonochem. 21 (2014) 1100-1107.

X. Ying, Y. Xu,Y. Lu,X. Liu,Z. Yin,W. Wu,et al. Enhanced dissolution and oral bioavailability of aripiprazolenanosuspensions prepared by nanoprecipitation/homogenization based on acid–base neutralization. Int. J. Pharm. 438 (2014) 287– 295.

Y. Xie, C. Hong,Y. Dang, G. Lin,Y. Yao, G. Li,et al. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: An in- vitro and in-vivo evaluation. Int. J. Pharm. 47 (2014) 251–260.

P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, C. Patrono,Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br. Med. J. 332 (2006) 1302-1305.

B. Yadav, Y.S. Tanwar, Development, characterization and in-vitro evaluation of flurbiprofen solid dispersions using polyethylene glycols as carrier. J.Appl. Pharm. Sci. 6(4) 2006 60-66.

G. Zhai, M. Sun, Y. Gao, Y. Pei, C. Guo, F. Cao,et al. Development of nanosuspension formulation for oral delivery of quercetin. J.Biomed.Nanotechn. 6 (2010) 325–332.

B.P. Sahu, M.K. Das,Nanosuspension for enhancement of oral bioavailability of felodipine. Appl. Nanosci. 4 (2014) 189–197.

Z. Attari, S. Kalvakuntla, M.S. Reddy, M. Deshpande, C.M. Rao, K.B. Koteshwara,Formulation and characterization of nanosuspensions of BCS class II and IV drugs by combinative method. J. Exp. Nanosci. 11(4) 2014) 276-288.

T. Higuchi, K.A. Connors, Phase-solubility techniques. Adv. Anal. Chem. Instrumen. 4 (1965) 117-212.

A.M. Cerdeira, M. Mazzotti, B. Gander,Formulation and drying of miconazole and itraconazolenanosuspensions. Int. J. Pharm. 443 (2013) 209– 220.

S.K. Singh,K.K. Srinivasan,K. Gowthamarajan,D.S. Singare,D. Prakash, N.B. Gaikwad, Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur. J. Pharm. Biopharm. 78 (2011) 441–446.

J.Y. Choi, J.Y. Yoo, H.S. Kwak, B.U. Nam, J. Lee, Role of polymeric stabilizers for drug nanocrystal dispersions. Curr. Appl. Phys. 5 (2005) 472–474.

M. Kakran, N.G. Sahoo, L. Li, Z. Judeh, Y. Wang, K. Chong, et al. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int. J. Pharm. 383(1-2) (2010)285–292.

S. Das, P.K. Suresh, Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface: Application to amphotericin B, Nanomedicine: Nanotech. Bio. Med. 7(2) (2011) 242–247.

S. Chandran, A. Roy, R.N. Saha, Effect of pH and formulation variables on in-vitrotranscorneal permeability of flurbiprofen: a technical note. AAPS Pharm. Sci. Tech. 9 (2008) 1031-1037.

A.A. Date, V.B. Patravale, Current Strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 9 (2004) 222–235.

Y. Lu, N. Tang, J.P. Qi, W. Wu, Phase solubility behavior of hydrophilic polymer/cyclodextrin/lansoprazole ternary system studied at high polymer concentration and by response surface methodology. Pharm. Dev. Technol. 17 (2012) 236–241.

R. Shegokar, R.H. Muller,Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399 (2010) 129–139.

R. Mauludin, J. Moschwitzer, R.H. Muller, Fast dissolving ibuprofen nanocrystal loaded solid dosage forms. Int. J. Pharm. Pharm. Sci. 4(3) (2012)543- 549.

B. Sinha, R.H. Muller, J.P. Moschwitzer, Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int. J. pharm., 453 (2013) 126–141.

R. Ravichandran, Development of an Oral CurcuminNanocrystal Formulation. J. Nanotechnol. Eng. Med. 3(4) (2003) 041007.

G.D. Wang, F.P. Mallet, F. Ricard, P.P. Heng Jerry, Pharmaceutical nanocrystals. Curr. Opin. Chem. Engg. 1(2) (2012) 102-107.

M. Nakarani, A.K. Misra, J.K. Patel, S.S. Vaghani, Itraconazole nanosuspension for oral delivery: Formulation,characterization and in vitrocomparison with marketed formulation. DARU, 18(2) (2010)84-90.

R.H. Muller, K. Peters, Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int. J. Pharm. 160 (1998) 229–237.

B.E. Rabinow, Nanosuspensions in drug delivery. Nature Rev. Drug. Disc. 3 (2004) 785–796.

J.U. Junghanns, R.H. Muller,Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3 (2008) 295–309.

S. Onoue, H. Takahashi, Y. Kawabata, Y. Seto, J. Hatanaka, B. Timmermann, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci. 99 (2010) 1871.

M.P. Kumar, Y.M. Rao, S. Apte, Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 4 (2008) 53-58.

R. Kumar, P.F. Siril, Preparation and characterization of polyvinyl alcohol stabilized griseofulvin nanoparticles. Mater Today: Proc. 3 (2016)2261–2267.

D. Sharma, M. Soni, S. Kumar, G.D. Gupta, Solubility enhancementeminent role in poorly soluble drugs. Res. J. Pharm. Tech. 2(2) (2009)220–224.

H. DeWaard, W. Hinrichs, H. Frijlink, A novel bottom–up process to produce drug nanocrystals: controlled crystallization during freeze drying. J. Control Release 128 (2008)179–83.